drugset
drugset / Trial / NCT00062491

Study of Karenitecin (BNP1350) to Treat Malignant Melanoma

NCT00062491 ↗

Phase 2 Completed 46 enrolled BioNumerik Pharmaceuticals, Inc. Crown Bioscience · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of Karenitecin (BNP1350) as a treatment for Malignant Melanoma.

Timeline

Start
2002-05
Primary completion
2003-06
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Cositecan Small molecule 1 mg/m2 Intravenous

Indications

melanoma